Abstract
Non-Melanoma Skin Cancer (NMSC) is the most common form of skin cancer. Common risk factors linked to the occurrence of NMSC are occupational exposure to chemicals, ultraviolet light exposure, immunosuppresion, human papillomavirus infection, artificial tanning, premalignant skin lesions and inherited skin conditions. The various clinical manifestations of NMSC depend on location and subtype. Management of NMSC includes pathology confirmation, staging and treatment. Retinoid and nicotinamide have been shown to be effective for the prevention of NMSC, primary treatments available for the treatment of NMSC are wide local excision, Mohs micrographic surgery (MMS), radiotherapy (RT), topical agents (5FU cream) and photodynamic therapy (PDT).
The choice of definite treatment depends on many factors such as performance status and age of the patient, location and size of the tumor, etc.Keywords: Non-melanoma skin cancer, MMS, PDT, BCC, SCC.
Current Cancer Therapy Reviews
Title:Non-Melanoma Skin Cancer – Overview
Volume: 12 Issue: 3
Author(s): Kurian Joseph
Affiliation:
Keywords: Non-melanoma skin cancer, MMS, PDT, BCC, SCC.
Abstract: Non-Melanoma Skin Cancer (NMSC) is the most common form of skin cancer. Common risk factors linked to the occurrence of NMSC are occupational exposure to chemicals, ultraviolet light exposure, immunosuppresion, human papillomavirus infection, artificial tanning, premalignant skin lesions and inherited skin conditions. The various clinical manifestations of NMSC depend on location and subtype. Management of NMSC includes pathology confirmation, staging and treatment. Retinoid and nicotinamide have been shown to be effective for the prevention of NMSC, primary treatments available for the treatment of NMSC are wide local excision, Mohs micrographic surgery (MMS), radiotherapy (RT), topical agents (5FU cream) and photodynamic therapy (PDT).
The choice of definite treatment depends on many factors such as performance status and age of the patient, location and size of the tumor, etc.Export Options
About this article
Cite this article as:
Joseph Kurian, Non-Melanoma Skin Cancer – Overview, Current Cancer Therapy Reviews 2016; 12 (3) . https://dx.doi.org/10.2174/1573394713666161214124214
DOI https://dx.doi.org/10.2174/1573394713666161214124214 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Writers and Erasers of Histone Lysine methylation with Clinically Applied Modulators: Promising Target for Cancer Therapy
Current Pharmaceutical Design Targeted Delivery of Anti-Inflammatory Agents to Tumors
Current Pharmaceutical Design Roles of Epithelial-Mesenchymal Transition in Cancer Drug Resistance
Current Cancer Drug Targets Eph Receptor Tyrosine Kinases in Tumor and Tumor Microenvironment
Current Pharmaceutical Design Understanding the Multifaceted Role of Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2) and its Altered Behaviour in Human Diseases
Current Molecular Medicine NK-1 Receptor Antagonists: A New Paradigm in Pharmacological Therapy
Current Medicinal Chemistry The Targets of Curcumin
Current Drug Targets Expression of mTOR/70S6K Signaling Pathway in Melanoma Cancer Cells and the Effects of Dacarbazine and Metformin
Current Cancer Therapy Reviews COX-2 and Colorectal Cancer
Current Pharmaceutical Design A Fluoro Derivative of Embelin, as Potent B-RAF Inhibitor in Melanoma
Anti-Cancer Agents in Medicinal Chemistry Targeting p73 - a Potential Approach in Cancer Treatment
Current Pharmaceutical Design Innovative Formulations for the Controlled and Site-specific Delivery of Antiinflammatory Drugs
Current Pharmaceutical Design Novel Agents in Anticancer Drug Therapy I (Antiangiogenic Agents, Egfr Inhibitors)
Medicinal Chemistry Reviews - Online (Discontinued) Leukotriene A4 Hydrolase as a Target for Cancer Prevention and Therapy
Current Cancer Drug Targets Renal Cell Carcinoma in a Patient with Rheumatoid Arthritis Treated with Adalimumab
Current Drug Safety Oxazole-Based Compounds As Anticancer Agents
Current Medicinal Chemistry Cell-Penetrating Peptides as Delivery Enhancers for Vaccine
Current Pharmaceutical Biotechnology Towards Understanding the Role of Cancer-Associated Inflammation in Chemoresistance
Current Pharmaceutical Design A New Approach for β-cyclodextrin Conjugated Drug Delivery System in Cancer Therapy
Current Drug Delivery Application of Phage Display Technology to Cancer Research
Current Pharmaceutical Biotechnology